logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

#WeWontRest until we beat Alzheimer’s disease – together

Source: www.epfia.eu

Unlocking the mystery behind Alzheimer’s disease and dementia and improving care for people require new types of partnership. As we navigate uncertain waters, we need to come together to explore the opportunities and barriers that arise and #WeWontRest until we beat Alzheimer’s disease – together.

On 23-25 October, I attended the Alzheimer Europe (AE) 29th annual conference focusing on “making valuable connections”. The conference offered a timely reminder of the global need to raise awareness around dementia and to deliver new tools to prevent, detect and treat Alzheimer’s and other forms of dementia. 50 million people live with dementia worldwide and this number is growing by almost 10 million each year – the equivalent of a new case every 3 seconds. It is listed by the World Health Organisation as the world’s 5th leading cause of death. Alzheimer Disease (AD) is the most common form of dementia and may contribute to 60–70% of cases. In this context, one can understand that the number of national dementia strategies is growing across Europe.
 
The AE conference touched upon a broad range of topics, from preclinical research to early detection, clinical trials, technology and e-health, implementation in Europe of coordinated actions on dementia (Joint Action on dementia), socio-economic aspects and innovation.
 
Research and innovation are at the heart of our contribution to defeating dementia. Industry and academic researchers have invested an enormous amount of time, energy and funding in the search for new biomarkers and better therapies. Despite frequent setbacks in clinical trials, scientific progress is advancing rapidly and industry continues to invest significantly: there are 135 clinical trials for Alzheimer’s disease in development and new avenues to explore as we search for ways to treat, slow or prevent Alzheimer’s disease. Giving up is simply not an option.
 
Looking ahead, there is reason for hope. Biogen and Eisai’s announcement that Biogen plans to pursue regulatory approval for aducanumab offers new hopes to patients with AD. Aducanumab could become the first approved therapy to reduce the rate of cognitive decline associated with early AD. This would be great news not only for people living with Alzheimer’s disease and their carers, but also for the science and research community.  It is a long road still ahead and we don’t know yet what the end result will be, but it is a welcome reminder that the industry and broader research community will not rest until we can offer new hope to patients living with Alzheimer’s and their families.
 
Prevention was also mentioned as a great hope for the future. A Finnish study on preventing cognitive impairment and disability (FINGER) highlighted very encouraging results. 30% of dementia cases are avoidable with a good diet, exercise, cognitive training and vascular risk monitoring. Many countries worldwide are now following the Finnish initiative and have established trials to test the efficacy of prevention for cognitive decline.
 
The conference also raised awareness about a number of technologies currently being developed to help improve the life of people living with AD, e.g. a pillow with sensitive areas that can activate sounds selected from the patient’s life to bring warm memories; devices that detect motions which play a pre-recorded message to remind a person to turn off the gas before leaving the house; devices that help keep track of the time and day; medication aids and locator devices.
 
During the conference, hope for the future came from all partners who are working together to improve the life of patients living with dementia. The pharmaceutical industry, through its EFPIA member companies, is also joining forces to reach a single goal: To ensure a brighter today and tomorrow for people with Alzheimer’s disease. We are committed to co-creating solutions with key stakeholders and agreeing on a common approach to ensure a better today and tomorrow for people with Alzheimer’s disease. We have highlighted our ideas in the paper “Taking Action Together to Ensure a Better Today and Tomorrow for People with Alzheimer’s Disease”.
 
Unlocking the mystery behind Alzheimer’s disease and dementia and improving care for people require new types of partnership. As we navigate uncertain waters, we need to come together to explore the opportunities and barriers that arise and #WeWontRest until we beat Alzheimer’s disease – together.

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.